Xencor, Inc. (NASDAQ:XNCR) VP Sells $665,547.28 in Stock

Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais sold 36,329 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total value of $665,547.28. Following the transaction, the vice president now owns 192,319 shares of the company’s stock, valued at approximately $3,523,284.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Xencor Stock Performance

Shares of XNCR traded up $0.74 during mid-day trading on Thursday, reaching $19.39. The company had a trading volume of 384,254 shares, compared to its average volume of 666,582. Xencor, Inc. has a 52-week low of $16.49 and a 52-week high of $26.84. The company has a quick ratio of 7.08, a current ratio of 7.08 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.20 billion, a P/E ratio of -8.52 and a beta of 0.69. The stock has a 50 day moving average of $21.52 and a two-hundred day moving average of $21.37.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.28). The company had revenue of $12.80 million during the quarter, compared to analysts’ expectations of $23.07 million. Xencor had a negative return on equity of 20.29% and a negative net margin of 82.23%. The firm’s quarterly revenue was down 32.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.02) EPS. On average, analysts expect that Xencor, Inc. will post -3.5 earnings per share for the current year.

Hedge Funds Weigh In On Xencor

A number of large investors have recently bought and sold shares of XNCR. CWM LLC raised its holdings in Xencor by 498.7% in the 4th quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,147 shares during the period. Parallel Advisors LLC raised its holdings in Xencor by 303.9% in the 4th quarter. Parallel Advisors LLC now owns 1,349 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,015 shares during the period. Signaturefd LLC raised its holdings in Xencor by 367.7% in the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,151 shares during the period. GAMMA Investing LLC raised its holdings in Xencor by 153.7% in the 1st quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,316 shares during the period. Finally, Allworth Financial LP raised its holdings in Xencor by 29,487.5% in the 4th quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 2,359 shares during the period.

Analyst Ratings Changes

A number of brokerages have weighed in on XNCR. BMO Capital Markets decreased their target price on Xencor from $34.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, June 14th. Wedbush reaffirmed an “outperform” rating and set a $34.00 target price (down from $36.00) on shares of Xencor in a research report on Thursday, June 13th. Royal Bank of Canada decreased their target price on Xencor from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Friday, June 14th. BTIG Research reduced their price target on Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research report on Tuesday, April 16th. Finally, Raymond James reduced their price target on Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research report on Friday, June 14th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.38.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.